The deal centers on Actio's small molecule for KCNT1-related epilepsy. Meanwhile, Actio will spin out a separate company with its other assets.

The investigator-initiated trial comes after Elicio said a Phase II trial of ELI-002 7P in adjuvant pancreatic cancer did not meet its primary endpoint.

NEW YORK – Opus Genetics has enrolled the final patient into its registrational Phase III clinical trial evaluating its investigational gene therapy for a severe, inherited retinal dystrophy, the ...

NEW YORK – Hangzhou, China-based CellOrigin has enlisted Walvax Biotechnology to help launch an investigator-initiated trial testing an in vivo GPC3-targeted CAR therapy in patients with ...

NEW YORK – As Verastem Oncology's approved product Avmapki Fakzynja Co-Pack (avutometinib and defactinib) is hitting its stride in ovarian cancer, the firm is turning its attention to its KRAS G12D ...

NEW YORK – Rocket Pharmaceuticals is discussing next steps to complete a pivotal Phase II trial of its Danon disease gene therapy, RP-A501, with the US Food and Drug Administration based on promising ...

NEW YORK – IQVIA will support Boston-based biopharma Medera Therapeutics' clinical trials of gene therapies for cardiovascular diseases, the companies announced Tuesday. Durham, North Carolina-based ...

Meanwhile, revenue from Casgevy reached $76.4 million, marking Vertex and CRISPR Therapeutics' highest quarterly sales from ...

The firm disclosed the update on the gene therapy, which it acquired in its 2021 purchase of Prevail Therapeutics, in its Q2 ...

NEW YORK – Intellia Therapeutics is preparing commercial launch activities for its CRISPR gene-editing treatment for hereditary angioedema (HAE), lonvoguran ziclumeran. Intellia initiated in the ...

The firm's personalized immunotherapy DISP-10 combines an engineered tumor-specific virus with BMS's CAR T-cell therapy Abecma.

The network of community oncology practices eventually hopes to integrate the tool with its genomic databases.